PMLive7h
FDA approves Exelixis’ Cabometyx to treat advanced neuroendocrine tumours
The US Food and Drug Administration (FDA) has approved Exelixis’ Cabometyx (cabozantinib) to treat advanced neuroendocrine ...
BioSpace15h
5 Big Pharmas Push Boundaries in Radiopharmaceuticals
While Novartis and Bayer got there first, AstraZeneca, Bristol Myers Squibb and Eli Lilly are all vying to bring their ...
PharmiWeb9h
Imfinzi approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the ...
Pharmabiz13h
EMA committee recommends approval of Bristol Myers Squibb’s subcutaneous formulation of Opdivo across multiple solid tumour indications
EMA committee recommends approval of Bristol Myers Squibb’s subcutaneous formulation of Opdivo across multiple solid tumour indications: Princeton, New Jersey Monday, March 31, ...
PharmiWeb3h
IMFINZI® (durvalumab) approved in the US as first…
AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...
Le Lézard7h
IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
AstraZeneca's IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...
American Cancer Society3h
Explaining Pancreatic Tumors: An Expert Q&A
Pancreatic cancer is on the rise in the United States, but there's another, less common type called pancreatic neuroendocrine ...
EMBO Press8h
Liver TET1 promotes metabolic dysfunction-associated steatotic liver disease
Liver TET1 was found to promote metabolic dysfunction-associated steatotic liver disease (MASLD) by regulating CD36 ...
Endocrinology Advisor16h
Cabometyx Approved for Advanced Neuroendocrine Tumors
The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.